Daily Cardiology Research Analysis
Three impactful cardiology studies stand out today: a meta-analysis of randomized trials shows CYP2C19 point-of-care genotyping to guide antiplatelet therapy reduces myocardial infarction and composite MACE after PCI; a multicenter registry suggests upgrading pacing-induced cardiomyopathy to conduction system pacing outperforms biventricular pacing; and a nationwide cohort links RSV infection to excess 1‑year cardiovascular events comparable to influenza, underscoring vaccine relevance.
Summary
Three impactful cardiology studies stand out today: a meta-analysis of randomized trials shows CYP2C19 point-of-care genotyping to guide antiplatelet therapy reduces myocardial infarction and composite MACE after PCI; a multicenter registry suggests upgrading pacing-induced cardiomyopathy to conduction system pacing outperforms biventricular pacing; and a nationwide cohort links RSV infection to excess 1‑year cardiovascular events comparable to influenza, underscoring vaccine relevance.
Research Themes
- Precision medicine in antiplatelet therapy
- Conduction system pacing for heart failure/device management
- Infection-related cardiovascular risk and vaccination policy
Selected Articles
1. Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis.
Across four RCTs (n=5,912), CYP2C19 point-of-care genotyping to personalize P2Y12 inhibitor selection reduced recurrent myocardial infarction and composite MACE after PCI versus standard care, without increasing bleeding. Cardiovascular death, stroke, and stent thrombosis were similar between strategies.
Impact: This meta-analysis of randomized trials provides high-level evidence that bedside genotyping can improve hard cardiovascular outcomes in PCI, advancing precision antiplatelet therapy from concept to clinical utility.
Clinical Implications: In ACS/CAD patients undergoing PCI, implementing CYP2C19 point-of-care genotyping to guide clopidogrel versus alternative P2Y12 inhibitors may reduce MI and MACE without excess bleeding, supporting genotype-guided pathways in catheterization labs and EDs.
Key Findings
- Genotype-guided therapy reduced recurrent myocardial infarction (RR 0.54, 95% CI 0.38–0.77).
- Composite major adverse cardiovascular events were lower with genotype guidance (RR 0.59, 95% CI 0.48–0.72).
- No significant differences were observed for cardiovascular death, stroke, stent thrombosis, or bleeding.
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials with low risk of bias and minimal heterogeneity.
- Prospective registration (PROSPERO) and dual independent review for study selection and data extraction.
Limitations
- Follow-up durations and specific P2Y12 regimens across trials are not detailed in the abstract.
- Generalizability may vary by healthcare setting and availability of point-of-care genotyping.
Future Directions: Head-to-head implementation trials comparing genotype-guided pathways versus universal potent P2Y12 inhibitor strategies, cost-effectiveness analyses, and integration with platelet function testing and polygenic risk may refine precision antiplatelet care.
OBJECTIVE: Evidence on the utility of CYP2C19 point-of-care (POC) testing to guide antiplatelet therapy selection in patients with acute coronary syndrome (ACS) or stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) is currently limited. To address this gap, a meta-analysis was conducted to assess the clinical impact of CYP2C19 POC genotyping in ACS patients treated with P2Y12 inhibitors in PCI settings. The study compared clinical outcomes between standard care and genotype-guided antiplatelet therapy in ACS or CAD patients undergoing PCI, leveraging POC genotyping for rapid therapy optimization. METHOD: PubMed, EMBASE, Cochrane, Scopus and ProQuest. Central databases were searched up to 30 August 2025, for studies evaluating the use of point-of-care CYP2C19 genotyping to guide antiplatelet therapy in ACS/CAD patients undergoing PCI, comparing clinical efficacy and safety with conventional P2Y12 inhibitors. Two independent reviewers assessed study eligibility, extracted data, and evaluated the risk of bias. Risk ratios (RRs) with 95% confidence intervals were computed using random-effects models, with study heterogeneity assessed by the I RESULTS: A total of four randomized controlled trials (RCTs) were included in the meta-analysis, comprising 5912 antiplatelet-treated ACS/CAD patients undergoing PCI. The analysis showed minimal statistical heterogeneity and low risk of bias. Compared with the standard treatment group, the genotype-guided group demonstrated a significantly lower risk of recurrent myocardial infarction (RR 0.54, 95% CI 0.38-0.77, P = 0.001). Although there were no significant differences in the efficacy outcomes for cardiovascular death, stroke, stent thrombosis, or bleeding complications, the calculated composite MACEs were significantly reduced in the genotype-guided group (RR 0.59, 95% CI 0.48-0.72, P = 0.001). CONCLUSION: Genotype-guided antiplatelet therapy using CYP2C19 POC genotyping prior to PCI in ACS/CAD patients may reduce the risk of recurrent myocardial infarction and composite MACEs compared to standard treatment, highlighting the importance of POC genotyping for facilitating rapid and effective therapeutic decision-making. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251157778, identifier CRD420251157778.
2. Effectiveness and safety of upgrading to conduction system pacing compared with biventricular pacing in patients with pacing-induced cardiomyopathy: Results of a propensity score-matched analysis from a multicenter registry.
In a multicenter propensity-matched cohort of PICM patients, upgrading to conduction system pacing reduced the composite of all-cause death or heart failure hospitalization and lowered procedure-related complications compared with biventricular pacing, with greater improvements in LVEF and NYHA class.
Impact: The study supports a paradigm shift toward conduction system pacing for PICM upgrades, indicating superior clinical outcomes and fewer complications versus current standard care.
Clinical Implications: For patients with PICM and high RV pacing burden, consider CSP (LBBAP or HBP) as the preferred upgrade strategy to improve survival/HF hospitalization and reverse remodeling, while potentially reducing procedural complications.
Key Findings
- Primary composite (all-cause death or HF hospitalization) was lower with CSP vs BVP (10.5% vs 29.8%; p=0.010) over 22.8 months.
- Procedure-related complications were less frequent with CSP (3.5%) than BVP (14.0%; p=0.047).
- CSP achieved greater improvements in LVEF (+15.3% vs +11.1%) and NYHA class (-1.3 vs -0.8) at 12 months.
Methodological Strengths
- Prospective multicenter registry with propensity score matching to balance baseline characteristics.
- Clinically meaningful endpoints with median follow-up of 22.8 months and device-specific complication tracking.
Limitations
- Observational design with potential residual confounding despite matching.
- CSP techniques (LBBAP vs HBP) and operator experience may influence outcomes and generalizability.
Future Directions: Randomized trials comparing CSP vs BVP for PICM upgrades, subgroup analyses (ischemic vs non-ischemic, QRS morphology), and long-term lead performance/safety data are needed.
BACKGROUND: Upgrading to biventricular pacing (BVP) is currently the standard treatment for pacing-induced cardiomyopathy (PICM) patients. Although emerging literature suggests that upgrading to conduction system pacing (CSP) (including His bundle pacing, HBP, and left bundle branch area pacing, LBBAP) could be an effective alternative to BVP in the treatment of PICM, comparative data between these two upgrading strategies are lacking. OBJECTIVE: To compare the effectiveness and safety of upgrading between CSP and BVP in a cohort of patients with PICM. METHODS: Prospective, multicenter, observational study enrolling 183 consecutive patients with PICM (54.1% with NYHA class >II, mean left ventricular ejection fraction, LVEF, 33.2±8.4%), who underwent upgrading to CSP (n=69, of which 52 LBBAP, 17 HBP) or BVP (n=114). Propensity matching for baseline characteristics yielded 57 matched pairs. The primary endpoint was a composite of all-cause death and heart failure hospitalization (HFH). Secondary endpoints included the incidence of procedure-related complications, and change in LVEF and in NYHA class from baseline to 12-month follow-up. RESULTS: During a median follow-up of 22.8 months, the primary endpoint occurred in 6 CSP patients (10.5%), and in 17 BVP patients (29.8%) (p=0.010). Procedure-related complications occurred in 2 CSP patients (3.5%), and in 8 BVP patients (14.0%) (p=0.047). Upgrading to CSP was associated with a significantly greater improvement in LVEF (+15.3±7.3 vs. +11.1±13.5%; p=0.039) and NYHA class (-1.3±0.7 vs. -0.8±0.8; p<0.001) at 12-month compared to BVP. CONCLUSIONS: In patients with PICM, upgrading to CSP could reduce the risk of all-cause death or HFH, as well as the incidence of procedure-related complications, compared to BVP.
3. Cardiovascular Events 1 Year After Respiratory Syncytial Virus Infection in Adults.
In a nationwide matched cohort of adults ≥45 years, laboratory-confirmed RSV infection was associated with a 4.69 percentage point excess risk of any cardiovascular event over 1 year, with strongest effects in hospitalized, older, and comorbid patients; risk magnitude was similar to influenza.
Impact: This large, well-controlled cohort quantifies sustained post-RSV cardiovascular risk, informing prevention strategies and prioritization of RSV vaccination among older and high-risk adults.
Clinical Implications: Clinicians should consider 1-year CV risk surveillance after RSV infection, especially in hospitalized, elderly, or comorbid patients, and advocate RSV vaccination alongside influenza vaccination to mitigate cardiovascular morbidity.
Key Findings
- Any cardiovascular event risk difference at 365 days after RSV infection was 4.69 percentage points (95% CI 4.02–5.36).
- Excess risk was highest among hospitalized patients (6.61 pp), older adults (e.g., 7.93 pp for age 85–94), and those with preexisting CVD (11.95 pp) or diabetes (7.50 pp).
- The 1-year cardiovascular risk after RSV was comparable to that after influenza infection.
Methodological Strengths
- Nationwide registry-based matched cohort with 1:1 matching on age, sex, and comorbidities.
- Use of Aalen-Johansen estimator for cumulative incidence and risk difference estimation with multiple control cohorts.
Limitations
- Observational design susceptible to residual confounding despite matching.
- RSV testing and case ascertainment may vary over time and care settings.
Future Directions: Evaluate mechanistic links between RSV and cardiovascular complications, assess risk mitigation via vaccination in pragmatic trials, and develop post-infection CV monitoring pathways.
IMPORTANCE: Respiratory syncytial virus (RSV) infection has recently been recognized as common among adults, but data on the burden of cardiovascular disease (CVD) beyond the immediate acute phase are lacking. OBJECTIVE: To estimate the 365-day absolute excess risk (risk difference) of composites of CVD and their individual components following laboratory-confirmed RSV infection in adults. DESIGN, SETTING, AND PARTICIPANTS: This nationwide, registry-based, matched cohort study was conducted using Danish national health registries. Adults aged 45 years or older on January 1, 2019, with a laboratory-confirmed RSV infection between January 1, 2019, and December 31, 2024, were matched 1:1 on age, sex, and preexisting comorbid conditions to individuals without RSV infection. Similar matched cohorts were established for influenza infection, hip fracture, and urinary tract infection without sepsis as control groups. EXPOSURE: Laboratory-confirmed RSV infection. MAIN OUTCOMES AND MEASURES: The primary outcomes were major adverse cardiovascular events, comprising ischemic heart disease, stroke, and heart failure, and any cardiovascular event, comprising major adverse cardiovascular events together with arrhythmias, venous thromboembolism, and inflammatory heart disease. Matched individuals were followed up for up to 365 days after the index date. Absolute risk differences and 95% CIs were calculated at 30 and 365 days using cumulative incidences derived from the Aalen-Johansen estimator. RESULTS: The study included 17 494 matched individuals (mean [SD] age, 71.8 [12.0] years; 57.6% female). At 365 days, 665 any cardiovascular events had occurred among 8747 individuals with RSV infection and 257 among 8747 individuals without infection, corresponding to a risk difference of 4.69 percentage points (95% CI, 4.02-5.36 percentage points). The largest 365-day risk differences for any cardiovascular event were observed in hospitalized patients (6.61 percentage points [95% CI, 5.70-7.52 percentage points]), older individuals (eg, 7.93 percentage points [95% CI, 5.34-10.53 percentage points] for those aged 85-94 years), and preexisting CVD (11.95 percentage points [95% CI, 8.80-15.10 percentage points ]) or diabetes (7.50 percentage points [95% CI, 4.53-10.47 percentage points]). The 1-year cardiovascular event risk following RSV was comparable to that following influenza infection. CONCLUSIONS AND RELEVANCE: This cohort study of adults aged 45 years or older with RSV infection found a significant excess risk of cardiovascular events over 1 year, comparable in magnitude to influenza infection. These findings underscore the importance of RSV as a potential risk factor for cardiovascular morbidity and highlight the need for vaccination to mitigate this burden.